754.14 USD
-4.77 (-0.63%)
754.14 USD
0 (0%)
Taking everything into account, REGN scores 6 out of 10 in our fundamental rating. REGN was compared to 528 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making REGN a very profitable company, without any liquidiy or solvency issues. REGN is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- REGN had positive earnings in the past year.
- In the past year REGN had a positive cash flow from operations.
- Each year in the past 5 years REGN has been profitable.
- REGN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 11.40%, REGN belongs to the top of the industry, outperforming 94.32% of the companies in the same industry.
- REGN has a better Return On Equity (14.79%) than 94.70% of its industry peers.
- With an excellent Return On Invested Capital value of 8.69%, REGN belongs to the best of the industry, outperforming 94.32% of the companies in the same industry.
- REGN had an Average Return On Invested Capital over the past 3 years of 12.44%. This is significantly below the industry average of 18.28%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROIC | 8.69% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
1.3 Margins
- Looking at the Profit Margin, with a value of 32.13%, REGN belongs to the top of the industry, outperforming 96.40% of the companies in the same industry.
- In the last couple of years the Profit Margin of REGN has grown nicely.
- REGN's Operating Margin of 27.61% is amongst the best of the industry. REGN outperforms 96.40% of its industry peers.
- In the last couple of years the Operating Margin of REGN has declined.
- Looking at the Gross Margin, with a value of 86.28%, REGN belongs to the top of the industry, outperforming 88.83% of the companies in the same industry.
- REGN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% |
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), REGN is creating some value.
- The number of shares outstanding for REGN remains at a similar level compared to 1 year ago.
- Compared to 5 years ago, REGN has less shares outstanding
- REGN has a better debt/assets ratio than last year.
2.2 Solvency
- REGN has an Altman-Z score of 7.50. This indicates that REGN is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of REGN (7.50) is better than 77.84% of its industry peers.
- REGN has a debt to FCF ratio of 0.70. This is a very positive value and a sign of high solvency as it would only need 0.70 years to pay back of all of its debts.
- The Debt to FCF ratio of REGN (0.70) is better than 94.70% of its industry peers.
- REGN has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.09, REGN is doing worse than 61.74% of the companies in the same industry.
- Even though the debt/equity ratio score it not favorable for REGN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 7.5 |
ROIC/WACC1.01
WACC8.59%
2.3 Liquidity
- A Current Ratio of 4.06 indicates that REGN has no problem at all paying its short term obligations.
- REGN has a Current ratio (4.06) which is in line with its industry peers.
- A Quick Ratio of 3.51 indicates that REGN has no problem at all paying its short term obligations.
- The Quick ratio of REGN (3.51) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
- REGN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.92%.
- REGN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.12% yearly.
- REGN shows a small growth in Revenue. In the last year, the Revenue has grown by 2.89%.
- The Revenue has been growing by 12.55% on average over the past years. This is quite good.
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
3.2 Future
- The Earnings Per Share is expected to grow by 7.62% on average over the next years.
- REGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.08% yearly.
EPS Next Y-3.81%
EPS Next 2Y0.46%
EPS Next 3Y6.66%
EPS Next 5Y7.62%
Revenue Next Year0.32%
Revenue Next 2Y3.45%
Revenue Next 3Y5.56%
Revenue Next 5Y6.08%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 16.75, which indicates a correct valuation of REGN.
- Based on the Price/Earnings ratio, REGN is valued cheaply inside the industry as 95.27% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Earnings ratio of 27.30, REGN is valued a bit cheaper.
- Based on the Price/Forward Earnings ratio of 16.37, the valuation of REGN can be described as correct.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of REGN indicates a rather cheap valuation: REGN is cheaper than 95.08% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.04, REGN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.75 | ||
| Fwd PE | 16.37 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, REGN is valued cheaper than 94.70% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of REGN indicates a rather cheap valuation: REGN is cheaper than 95.45% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.42 | ||
| EV/EBITDA | 15.27 |
4.3 Compensation for Growth
- The excellent profitability rating of REGN may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.28
EPS Next 2Y0.46%
EPS Next 3Y6.66%
5. Dividend
5.1 Amount
- With a yearly dividend of 0.44%, REGN is not a good candidate for dividend investing.
- Compared to an average industry Dividend Yield of 1.26, REGN pays a better dividend. On top of this REGN pays more dividend than 98.30% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.92, REGN's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.44% |
5.2 History
- REGN does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y0.46%
EPS Next 3Y6.66%
754.14
-4.77 (-0.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-28 2025-10-28/bmo
Earnings (Next)01-30 2026-01-30/amc
Inst Owners90.13%
Inst Owner Change-0.04%
Ins Owners1.95%
Ins Owner Change3.45%
Market Cap79.26B
Revenue(TTM)14.25B
Net Income(TTM)4.58B
Analysts79.44
Price Target808.25 (7.18%)
Short Float %2.71%
Short Ratio2.67
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.44% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.37%
Min EPS beat(2)20.96%
Max EPS beat(2)49.77%
EPS beat(4)3
Avg EPS beat(4)16.75%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.92%
EPS beat(12)10
Avg EPS beat(12)9.47%
EPS beat(16)13
Avg EPS beat(16)8.82%
Revenue beat(2)2
Avg Revenue beat(2)6.19%
Min Revenue beat(2)2.66%
Max Revenue beat(2)9.72%
Revenue beat(4)2
Avg Revenue beat(4)0.54%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.34%
Revenue beat(12)8
Avg Revenue beat(12)1.48%
Revenue beat(16)12
Avg Revenue beat(16)2.04%
PT rev (1m)1.54%
PT rev (3m)8.5%
EPS NQ rev (1m)-0.2%
EPS NQ rev (3m)16.02%
EPS NY rev (1m)-0.1%
EPS NY rev (3m)10.29%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)4.37%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)2.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.75 | ||
| Fwd PE | 16.37 | ||
| P/S | 5.56 | ||
| P/FCF | 20.42 | ||
| P/OCF | 15.63 | ||
| P/B | 2.56 | ||
| P/tB | 2.68 | ||
| EV/EBITDA | 15.27 |
EPS(TTM)45.01
EY5.97%
EPS(NY)46.06
Fwd EY6.11%
FCF(TTM)36.93
FCFY4.9%
OCF(TTM)48.25
OCFY6.4%
SpS135.56
BVpS294.56
TBVpS281.42
PEG (NY)N/A
PEG (5Y)1.28
Graham Number546.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROCE | 11.01% | ||
| ROIC | 8.69% | ||
| ROICexc | 11.38% | ||
| ROICexgc | 11.99% | ||
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% | ||
| FCFM | 27.24% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
ROICexc(3y)18.09%
ROICexc(5y)25.25%
ROICexgc(3y)19.06%
ROICexgc(5y)25.84%
ROCE(3y)15.75%
ROCE(5y)22.96%
ROICexgc growth 3Y-32.64%
ROICexgc growth 5Y-8.74%
ROICexc growth 3Y-33.7%
ROICexc growth 5Y-9.6%
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.61 | ||
| Cap/Depr | 226.62% | ||
| Cap/Sales | 8.35% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.73% | ||
| Profit Quality | 84.78% | ||
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 | ||
| Altman-Z | 7.5 |
F-Score5
WACC8.59%
ROIC/WACC1.01
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.76%
Profit Quality(5y)77.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
EPS Next Y-3.81%
EPS Next 2Y0.46%
EPS Next 3Y6.66%
EPS Next 5Y7.62%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
Revenue Next Year0.32%
Revenue Next 2Y3.45%
Revenue Next 3Y5.56%
Revenue Next 5Y6.08%
EBIT growth 1Y-6.18%
EBIT growth 3Y-22.95%
EBIT growth 5Y9.54%
EBIT Next Year-5.21%
EBIT Next 3Y6.05%
EBIT Next 5Y11.85%
FCF growth 1Y-10.97%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y-2.93%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%
REGENERON PHARMACEUTICALS / REGN FAQ
Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 6 / 10 to REGN.
What is the valuation status of REGENERON PHARMACEUTICALS (REGN) stock?
ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (REGN). This can be considered as Fairly Valued.
Can you provide the profitability details for REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (REGN) has a profitability rating of 8 / 10.
What is the financial health of REGENERON PHARMACEUTICALS (REGN) stock?
The financial health rating of REGENERON PHARMACEUTICALS (REGN) is 8 / 10.